Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | JAK2 over exp |
Therapy | Ruxolitinib + ZSTK474 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 over exp | Advanced Solid Tumor | sensitive | Ruxolitinib + ZSTK474 | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790). | 24251790 |
PubMed Id | Reference Title | Details |
---|---|---|
(24251790) | Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. | Full reference... |